Introduction Numerous PrEP Clinical trials have shown that oral antiretroviral (ARVs) containing tenofovir disoproxil fumarate (TDF) or tenofovir/emtricitabine (TDf/FTC) used by HIV-negative individuals to prevent HIV acquisition, called oral Pre-Exposure Prophylaxis (PrEP), are safe and effective in several populations. Prior modeling work suggests that oral PrEP is most cost-effective when targeted to populations at highRead more